Fig. 8

In vivo efficacy of ITC-6102RO in B7-H3-positive lung cancer PDX models. (A) Therapeutic efficacy of ITC-6102RO in 11C38 lung cancer PDX model. The drug was intravenously injected at 0.3 or 0.6 mg/kg, once, n = 5. (B) Therapeutic efficacy of ITC-6102RO in 15C63 lung cancer PDX models. The drug was intravenously injected at 0.15 or 0.3 mg/kg, once, n = 5. B7-H3 expression in tumor tissue was detected using IHC (brown, DAB-stained B7-H3; blue, hematoxylin-stained nuclei, scale bar, 50 μm). Data values represent the mean ± standard deviation. ***p < 0.001